Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis.
BACKGROUND
We performed a meta-analysis of the risk of cutaneous toxicities associated with immune checkpoint inhibitors.


METHODS
Eligible studies included randomized trials of patients with solid tumors on immune checkpoint inhibitors (ipilimumab, nivolumab, tremelimumab, pidlizumab and pembrolizumab); describing events of rash, vitiligo and pruritus.


RESULTS
A total of nine clinical trials were considered eligible for the meta-analysis. The relative risk of all-grade rash, vitiligo and pruritus was 4.06 (95% CI: 3.35-4.91; p < 0.0001), 16.3 (95% CI: 3.21-82.8; p = 0.0008) and 3.4 (95% CI: 2.24-5.16; p < 0.00001), respectively.


CONCLUSIONS
Our meta-analysis demonstrates that immune checkpoint inhibitors are associated with an increased risk of all grade skin rash, vitiligo and pruritus. Clinicians should perform regular clinical cutaneous monitoring.
Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Omar
O
Abdel-Rahman
Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Hesham
H
ElHalawani
Medical Microbiology & Immunology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Mona
M
Fouad
D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D058990:Molecular Targeted Therapy / Q000009:adverse effects*; D009369:Neoplasms / Q000150:complications* / Q000188:drug therapy; D016017:Odds Ratio; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D012871:Skin Diseases / Q000453:epidemiology / Q000209:etiology*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents
ipilimumab; nivolumab; pruritus; rash; vitiligo